» Articles » PMID: 22038577

Haloperidol Dosing Strategies in the Treatment of Delirium in the Critically Ill

Overview
Journal Neurocrit Care
Specialty Critical Care
Date 2011 Nov 1
PMID 22038577
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Delirium is the most common mental disturbance in critically-ill patients and results in significant morbidity and mortality. Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects. Despite its widespread use in the critical care setting, most of the relevant data are obtained from case series or extrapolated from non-critically-ill populations. This review provides an overview of haloperidol pharmacokinetics and a comprehensive summary of the evidence for various haloperidol dosing regimens in the treatment of delirium in critically-ill patients. A comprehensive literature search was conducted in Medline, Embase, and International Pharmaceutical Abstracts with "haloperidol", "delirium", "agitation", "critically-ill", and "intensive care" as keywords. Studies involving haloperidol for delirium prophylaxis, non-critical care settings, and terminally-ill subjects were excluded. Eleven studies were identified: four with intermittent IV haloperidol, four with continuous IV infusion haloperidol, two with oral/enteral haloperidol, and one with IM haloperidol. All of the case reports, case series, and descriptive studies have shown a benefit with haloperidol, but publication bias is likely present. Only three studies were controlled studies, but all had small sample sizes and methodological flaws. Randomized, double-blind, active-comparator trials of haloperidol with allocation concealment are needed. Subsequent research should focus on using validated delirium screening and assessment scales for more objective identification and measurement of delirium outcomes.

Citing Articles

Haloperidol for the treatment of delirium in ICU patients: a systematic review and meta‑analysis.

Zhao Y, Wang Q, Sun B, Li Y, Meng C, Miao G Eur J Med Res. 2025; 30(1):147.

PMID: 40025536 PMC: 11871728. DOI: 10.1186/s40001-025-02409-6.


Risk factors, preventive interventions, overlapping symptoms, and clinical measures of delirium in elderly patients.

Mei X, Liu Y, Han Y, Zheng C World J Psychiatry. 2024; 13(12):973-984.

PMID: 38186721 PMC: 10768493. DOI: 10.5498/wjp.v13.i12.973.


Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?.

Li L, Sassen S, van der Jagt M, Endeman H, Koch B, Hunfeld N Pharmaceutics. 2022; 14(3).

PMID: 35335925 PMC: 8950491. DOI: 10.3390/pharmaceutics14030549.


Successful management of delirium with dexmedetomidine in a patient with haloperidol-induced neuroleptic malignant syndrome: A case report.

Yang C, Chiu C, Yeh Y, Chao A World J Clin Cases. 2022; 10(2):625-630.

PMID: 35097088 PMC: 8771406. DOI: 10.12998/wjcc.v10.i2.625.


Challenges in Treating Cancer Patients With Unstable Psychiatric Disorder.

Bellman V, Russell N, Depala K, Dellenbaugh A, Desai S, Vadukapuram R World J Oncol. 2021; 12(5):137-148.

PMID: 34804276 PMC: 8577605. DOI: 10.14740/wjon1402.


References
1.
Jann M, Saklad S, Ereshefsky L, Richards A, Harrington C, Davis C . Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl). 1986; 90(4):468-70. DOI: 10.1007/BF00174062. View

2.
Milbrandt E, Deppen S, Harrison P, Shintani A, Speroff T, Stiles R . Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004; 32(4):955-62. DOI: 10.1097/01.ccm.0000119429.16055.92. View

3.
Skrobik Y, Bergeron N, Dumont M, Gottfried S . Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2003; 30(3):444-9. DOI: 10.1007/s00134-003-2117-0. View

4.
Wesley Ely E, Shintani A, Truman B, Speroff T, Gordon S, Harrell Jr F . Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004; 291(14):1753-62. DOI: 10.1001/jama.291.14.1753. View

5.
Arana G, Goff D, Friedman H, Ornsteen M, Greenblatt D, Black B . Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?. Am J Psychiatry. 1986; 143(5):650-1. DOI: 10.1176/ajp.143.5.650. View